Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9586955 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
Feb, 2033
(8 years from now) | |
US9969754 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
May, 2035
(11 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11827646 | GENENTECH INC | Compounds for treating spinal muscular atrophy |
Jan, 2036
(11 years from now) | |
US11534444 | GENENTECH INC | Treatment of SMA |
Oct, 2038
(14 years from now) |
Evrysdi is owned by Genentech Inc.
Evrysdi contains Risdiplam.
Evrysdi has a total of 4 drug patents out of which 0 drug patents have expired.
Evrysdi was authorised for market use on 07 August, 2020.
Evrysdi is available in for solution;oral dosage forms.
Evrysdi can be used as treatment of spinal muscular atrophy.
Drug patent challenges can be filed against Evrysdi from 07 August, 2024.
The generics of Evrysdi are possible to be released after 04 October, 2038.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-334) | Aug 07, 2027 |
New Chemical Entity Exclusivity(NCE) | Aug 07, 2025 |
Orphan Drug Exclusivity(ODE-400) | May 27, 2029 |
New Patient Population(NPP) | May 27, 2025 |
M(M-270) | Oct 03, 2026 |
Drugs and Companies using RISDIPLAM ingredient
NCE-1 date: 07 August, 2024
Market Authorisation Date: 07 August, 2020
Treatment: Treatment of spinal muscular atrophy
Dosage: FOR SOLUTION;ORAL